Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.
Bang K, Casadei-Gardini A, Yoo C, Iavarone M, Ryu MH, Park SR, Kim HD, Yoon YI, Jung DH, Park GC, Ahn CS, Moon DB, Hwang S, Kim KH, Song GW, Mazzarelli C, Alimenti E, Chan SL, De Giorgio M, Ryoo BY, Lee SG. Bang K, et al. Among authors: chan sl. Cancer Med. 2023 Feb;12(3):2572-2579. doi: 10.1002/cam4.5123. Epub 2022 Aug 5. Cancer Med. 2023. PMID: 36812124 Free PMC article.
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Ma BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray RD, Wong SC, To KF, King AD, Ahuja A, Chan AT. Ma BB, et al. Among authors: chan c, chan at, chan sl. Cancer. 2013 Dec 1;119(23):4145-53. doi: 10.1002/cncr.28327. Epub 2013 Oct 1. Cancer. 2013. PMID: 24114668 Free article. Clinical Trial.
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.
Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW, Tada T, Iñarrairaegui M, Vogel A, Schweitzer N, Chan SL, Sangro B, Kumada T, Johnson PJ. Toyoda H, et al. Among authors: chan sl, chan aw. Br J Cancer. 2016 Mar 29;114(7):744-50. doi: 10.1038/bjc.2016.33. Br J Cancer. 2016. PMID: 27022825 Free PMC article.
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.
Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ. Waked I, et al. Among authors: chan sl. Br J Cancer. 2017 Feb 14;116(4):448-454. doi: 10.1038/bjc.2016.423. Epub 2017 Jan 26. Br J Cancer. 2017. PMID: 28125820 Free PMC article.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Abou-Alfa GK, et al. Among authors: chan sl. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. N Engl J Med. 2018. PMID: 29972759 Free PMC article. Clinical Trial.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Finn RS, et al. Among authors: chan sl. J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2. J Clin Oncol. 2020. PMID: 31790344 Clinical Trial.
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. Kelley RK, et al. Among authors: chan sl. ESMO Open. 2020 Aug;5(4):e000714. doi: 10.1136/esmoopen-2020-000714. ESMO Open. 2020. PMID: 32847838 Free PMC article. Clinical Trial.
694 results